PATENT CLAIM ANALYSIS

Application Number: 16211139
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-04
Patent Classification: ["514", "253120"]

Abstract:
The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.

Claim (Index 2):
A combination according to  claim 1 , wherein the one or more therapeutically active agents is an anti-cancer agent which is selected from:\n Tyrosine kinase inhibitors; Vascular Endothelial Growth Factor (VEGF) receptor inhibitors; Platelet-derived Growth Factor (PDGF) receptor inhibitors; Fibroblast Growth Factor Receptor (FGFR) Inhibitors; Aurora kinase inhibitors; Cyclin-Dependent Kinase (CDK) inhibitors; Checkpoint Kinase (CHK) inhibitors; 3-Phosphoinositide-dependent kinase-1 (PDK1 or PDPK1) inhibitors; Pyruvate Dehydrogenase Kinase (PDK) inhibitors; Protein Kinase B (PKB) or AKT inhibitors; Protein Kinase C (PKC) activators; B-RAF inhibitors; C-RAF Inhibitors; Human Granulocyte colony-stimulating factor (G-CSF) modulators; RET Inhibitors; FMS-like Tyrosine kinase 3 (FLT3) Inhibitors or CD135; c-KIT Inhibitors; Bcr/Abl kinase inhibitors; IGF-1R inhibitors; PIM Kinase inhibitors; MET inhibitors; Human Epidermal Growth Factor Receptor 2 (HER2 receptor) inhibitors; Epidermal growth factor receptor (EGFR) inhibitors; Hedgehog antagonists; mTOR inhibitors; Phosphoinositide 3-kinase (PI3K) inhibitors; Bcl-2 protein family inhibitors; Mitogen-activated protein kinase (MEK) inhibitors; P38 MAPK inhibitors; JAK inhibitors; Alkylating agents; Aromatase inhibitors; Topoisomerase I inhibitors; Topoisomerase II inhibitors; DNA Synthesis inhibitors; Folate Antagonists or Antifolates; Immunomodulators; Proapoptotic receptor agonists (PARAs); Phospholipase A2 (PLA 2 ) inhibitors; SRC inhibitors; Osteoclastic bone resorption inhibitors; G-Protein-coupled Somatostatin receptors Inhibitors; Interleukin-11 and Synthetic Interleukin-11 (IL-11); Erythropoietin and Synthetic erythropoietin; Receptor Activator for Nuclear Factor \u03ba B (RANK) inhibitors; Thrombopoietin mimetic peptibodies; Cell growth stimulators; Histone deacetylase (HDAC) inhibitors; Biologic response modifiers; Anti-tumor antibiotics; Anti-microtubule or Anti-mitotic agents; Plant Alkaloids; Taxane anti-neoplastic agents; Cathepsin K inhibitors; Epothilone B analogs; Heat Shock Protein (HSP) inhibitors; Farnesyl Transferase Inhibitors (FTI); Thrombopoietin (TpoR) agonists such as Eltrombopag (SB497115, Promacta\u00ae and Revolade\u00ae); and Romiplostim (Nplate\u00ae); Proteosome inhibitors; Kinesis Spindle Protein (KSP) inhibitors; Polo-like kinase (Plk) inhibitors; Adrenal steroid inhibitors; Anti-androgens; Anabolic Steroids; Proteasome inhibitors; Gonadotropin-releasing hormone (GnRH) receptor agonists; HPV vaccines; Iron Chelating agents; Anti-metabolites; Bisphosphonates; Demethylating agents; Retinoids; Cytokines; Estrogen receptor downregulators; Anti-estrogens; Selective estrogen receptor modulators (SERMs); Leutinizing hormone releasing hormone (LHRH) agonists; Progesterones; 17\u03b1-hydroxylase/C17,20 lyase (CYP17A1) inhibitors; Miscellaneous cytotoxic agents; C\u2014C Chemokine receptor 4 (CCR4) Antibody; CD20 antibodies; CD20 Antibody Drug Conjugates; CD22 Antibody Drug Conjugates; CD33 Antibody Drug Conjugates; CD40 antibodies; CD52 antibodies; Anti-CS1 antibodies; CTLA-4 antibodies; p53-MDM2 inhibitors; and p53 activators.

Metadata:
- Claim Count in Document: 1.0
- Percentile: 98.0
- Lexical Diversity: 1.4
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15561189', '14972984', '15357195', '14522721', '14858029']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7769681400985061
- 35 USC 102 Novelty (BERT): 0.5455777557261687
- Combined Prediction Score: 0.7538291016612724
- Mean Citation Score: 338.9025539999999
- Max Citation Score: 383.7434
- Similarity Product: 245.62898194539548

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test